Furthermore, BRAF and NRAS mutations are mutually exclusive, as well as TERT C250T and C228T, and then, a maximum of two mutations will be tested in plasma for each melanoma patients, making feasible the dPCR approach proposed in this study. Here, BRAF is linked to melanoma.